

Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.



CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

May 12, 2026

To

BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Press Release

We refer to our letter dated May 12, 2026 enclosing the press release pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and would like to inform you that there was an error in the Earning call link shared in the press release.

We are enclosing the Press Release on the Financial Results of the Company for the quarter and year ended March 31, 2026, with the updated earning call link. The link is also provided hereunder:

[Earning call link](#)

The Press Release is also being uploaded on the website of the Company at www.neulandlabs.com

This is for your information and records.

Yours sincerely,

For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above



Neuland Q4FY26 Total income at Rs.2053.1 crore; EBITDA at Rs.603.4 crore

Hyderabad, India, May 12, 2026 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the year ended Mar 31st, 2026.

Commenting on the performance Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, Neuland Laboratories added *“We are pleased with the fact that we have ended FY26 on a strong note in line with our original expectations. There is good business visibility in the short to medium term anchored by commercial and near-commercial molecules. Our focus on execution discipline, customer satisfaction, and protection of business fundamentals is central to ensuring this phase of growth.*

At the same time, we are laying the groundwork for growth beyond this horizon. Key elements of this foundation are the investments in Peptide Manufacturing as well as the new R&D Centre, which are proceeding according to plan. Our Business Development strategy is aligned to the investments and is focused on bringing in the right kind of projects that support high quality, sustainable growth.”

Financial Summary

Particulars (Rs Cr)	Rs. crore				
	Q4FY26	Q4FY25	YoY (%)	Q3FY26	QoQ (%)
Total Income	788.7	335.8	134.9%	447.8	76.1%
EBITDA	319.4	58.2	448.6%	85.0	275.8%
EBITDA Margin	40.5%	17.3%	2316 bps	19.0%	2151 bps
Exceptional Item*		-			-
Profit Before Tax*	287.0	39.0	636.6%	54.3	428.9%
PBT Margin	36.4%	11.6%	2479 bps	12.1%	2430 bps
Profit After Tax	212.5	27.7	666.3%	40.4	425.8%

Q4 FY26 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST on Tuesday, May 12, 2026** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 1000+ Regulatory filings across the US (75 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi / Minakshi Machutre

EY IR

Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com